[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Cordis Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":91},{"warningLetters":4,"total":90},[5,31,54,71],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":27,"delivery_method":28,"recipient_title":19,"reference_number":29,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},474,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-14T05:00:00Z\">11\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flowkeydiscom-719647-11142025\">lowkeydis.com\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2502372\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>lowkeydis.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:directconnect222@gmail.com\"> directconnect222@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:store+56747458733@t.shopifyemail.com\"> store+56747458733@t.shopifyemail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello.cake.info@gmail.com\"> hello.cake.info@gmail.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 14, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Flowkeydis.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: Fog Off 50,000 Puff - Grape Slush and Fog Off 50,000 Puff - Blue Razz Ice.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. §387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2502372, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue Silver Spring, MD 20993-0002&nbsp;\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003Cbr>Contact Privacy Inc. Customer 0163043946\u003Cbr>lowkeydis.com@contactprivacy.com\u003C\u002Fp>\u003Cp>Tucows, Inc.\u003Cbr>domainabuse@tucows.com\u003C\u002Fp>\u003Cp>Shopify, Inc.\u003Cbr>abuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\nRW2502372\n\nProduct:\n\nTobacco\n\nRecipient:\n\nlowkeydis.com\n\nUnited States\n\ndirectconnect222@gmail.com\n\nstore+56747458733@t.shopifyemail.com\n\nhello.cake.info@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 14, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Flowkeydis.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order, including: Fog Off 50,000 Puff - Grape Slush and Fog Off 50,000 Puff - Blue Razz Ice.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. §387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2502372, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue Silver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA Electronic Mail\ncc:\nContact Privacy Inc. Customer 0163043946\nlowkeydis.com@contactprivacy.com\nTucows, Inc.\ndomainabuse@tucows.com\nShopify, Inc.\nabuse@shopify.com","lowkeydis.com","lowkeydiscom-719647-11142025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flowkeydiscom-719647-11142025","2026-10-26T08:09:16.547657+00:00","Warning Letter","Issued","2025-11-18","719647","Tobacco","2026-08-19T14:27:19.878+00:00","VIA Electronic Mail","RW2502372","2025-11-14",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":37,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},3320,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-06-01T13:20:00Z\">06\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-11T04:00:00Z\">05\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-614021-05112021\">Utah Cord Bank LLC\u003C\u002Fa>","Office Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)\u003Cbr \u002F>\r\n","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eliott D. Spencer, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Utah Cord Bank LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8675 S Sandy Parkway, Bldg. 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sandy\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84070\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 11, 2021\u003C\u002Fp>\n\n\u003Cp>[Warning Letter #OBPO 21-614021]\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Spencer:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Utah Cord Bank, LLC, located at 8675 S Sandy Parkway, Bldg. 110, Sandy, UT 84070 from February 1-11, 2021. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs)\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>&nbsp;set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 [21 CFR 1271], and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C 264].\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the items discussed below. All items below pertain to HCT\u002FPs recovered from donors between May 25, 2005 and February 11, 2021. Following our review of the information collected during the inspection, we identified additional concerns that are also included below.\u003C\u002Fp>\n\n\u003Cp>1.&nbsp; Failure to validate and approve a process according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests. The validation activities and results must be documented, including the date and signature of the individual(s) approving the validation [21 CFR 1271.230(a)]. For example:\u003C\u002Fp>\n\n\u003Cp>a.&nbsp;&nbsp; &nbsp;You failed to validate your process, which cannot be fully verified, used in the manufacture of HCT\u002FPs to ensure that your process does not cause contamination or cross-contamination and prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>b.&nbsp;&nbsp; &nbsp;Processing is defined at 21 CFR 1271.3(ff) and includes testing for microorganisms. &nbsp;You failed to validate your microbiological testing, which cannot be fully verified, used in the manufacture of HCT\u002FPs to ensure that your process prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>2.&nbsp;&nbsp;Failure to adequately monitor environmental conditions and provide proper conditions for operations, where environmental conditions could reasonably be expected to cause contamination or cross-contamination of HCT\u002FPs or equipment, or accidental exposure of HCT\u002FPs to communicable disease agents [21 CFR 1271.195(c)]. For example, the steps in processing HCT\u002FPs you described to the investigators during the inspection include exposing the unit of cord blood to the environment by draining the umbilical cord blood from the original collection bag into \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;vials. These conditions could reasonably be expected to cause contamination or cross-contamination of the HCT\u002FPs, however, you do not monitor environmental conditions in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;for the presence of microorganisms.&nbsp;\u003C\u002Fp>\n\n\u003Cp>3.&nbsp;&nbsp;Failure to establish and maintain procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT\u002FPs. You must design these procedures to prevent circumstances that increase the risk of the introduction, transmission, or spread of communicable diseases through the use of HCT\u002FPs [21 CFR 1271.180(a)]. For example, you have not established and maintained procedures that include, but are not limited to the following: &nbsp;\u003C\u002Fp>\n\n\u003Cp>a.&nbsp;&nbsp; &nbsp;Facilities (i.e.: maintenance\u002Frepairs, cleaning, sanitation) [21 CFR 1271.190(d)];\u003Cbr>\nb.&nbsp;&nbsp; &nbsp;Environmental control [21 CFR 1271.195];\u003Cbr>\nc.&nbsp;&nbsp; &nbsp;Equipment (i.e.: maintenance, cleaning, calibration) [21 CFR 1271.200(b)];\u003Cbr>\nd.&nbsp;&nbsp; &nbsp;Verification of supplies and reagents [21 CFR 1271.210];\u003Cbr>\ne.&nbsp;&nbsp; &nbsp;Processing and processing controls [21 CFR 1271.220];\u003Cbr>\nf.&nbsp;&nbsp; &nbsp;Labeling controls [21 CFR 1271.250];\u003Cbr>\ng.&nbsp;&nbsp; &nbsp;Storage [21 CFR 1271.260]; and\u003Cbr>\nh.&nbsp;&nbsp; &nbsp;Receipt, predistribution shipment, and distribution, including release criteria and shipping conditions [21 CFR 1271.265].\u003C\u002Fp>\n\n\u003Cp>4.&nbsp;&nbsp; &nbsp;Failure to maintain records concurrently with the performance of each step required in Subpart D and Subpart C of 21 CFR 1271. The records must identify the person performing the work and the dates of the various entries, and must be as detailed as necessary to provide a complete history of the work performed and to relate the records to the particular HCT\u002FP involved [21 CFR 1271.270(a)]. For example, you have not maintained complete records that include, but are not limited to, the following: &nbsp;\u003C\u002Fp>\n\n\u003Cp>a.&nbsp;&nbsp; &nbsp;Facility cleaning and sanitation [21 CFR 1271.190(d)];\u003Cbr>\nb.&nbsp;&nbsp; &nbsp;Environmental control and monitoring activities [21 CFR 1271.195(d)];\u003Cbr>\nc.&nbsp;&nbsp; &nbsp;Equipment maintenance, cleaning, sanitizing, and calibration [21 CFR 1271.200(e)];\u003Cbr>\nd.&nbsp;&nbsp; &nbsp;Receipt, verification, and lot number of each supply and\u002For reagent used in the manufacture of HCT\u002FPs [21 CFR 1271.210(d)];\u003Cbr>\ne.&nbsp;&nbsp; &nbsp;Storage temperatures [21 CFR 1271.260(e)];\u003Cbr>\nf.&nbsp;&nbsp; &nbsp;Recovery [21 CFR 1271.215];\u003Cbr>\ng.&nbsp;&nbsp; &nbsp;Processing (including sterility testing) [21 CFR 1271.220]; and\u003Cbr>\nh.&nbsp;&nbsp; &nbsp;Complaints [21 CFR 1271.320(b)].\u003C\u002Fp>\n\n\u003Cp>Based on the information obtained during the inspection and stated in your FDA 483 correspondence, it is unclear whether your products are intended for autologous use only, or whether they are also intended for allogeneic use in a first-degree or second-degree blood relative. Please clarify all potential uses of your products. Donor-eligibility determination, Subpart – C of 21 CFR 1271, is based on donor screening and testing for relevant communicable disease agents and diseases (described in §1271.50) and is required for all donors used in HCT\u002FPs except as outlined under §1271.90.\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. &nbsp;It is your responsibility to ensure that your establishment is in compliance with all the applicable requirements of the federal regulations. &nbsp;You are responsible for reviewing your firm’s operations as a whole to ensure that you fully comply with the law.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letters dated March 5, 2021 and April 16, 2021, in response to the Form FDA 483 issued to you on February 11, 2021. We have reviewed your responses in which you state that you have retained the services of a consultant. However, other than retaining the services of a consultant, your response is silent regarding specific corrective actions to address the violations outlined above. &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. &nbsp;Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. &nbsp;If you believe that your product is not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. &nbsp;If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and time frame within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Marc Jackson, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, DFC – BLDG 20 – W 6th Ave &amp; Kipling St., Denver, CO 80225, or emailed to Marc.Jackson@fda.hhs.gov. If you should have any questions, please contact Marc Jackson, Compliance Officer at (303) 236-3083 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;This letter applies solely to products manufactured for autologous use or, depending on your response to FDA's request at the close of this letter, any products manufactured for allogeneic use in a first-degree or&nbsp;second-degree blood relative. Accordingly, references in this letter to HCT\u002FPs or \"products\" do not include&nbsp;products manufactured by your firm&nbsp;that are not for autologous use or allogeneic use in a first-degree or&nbsp;second-degree blood relative. FDA intends to communicate with Utah Cord Bank, LLC separately&nbsp;regarding these products.&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nEliott D. Spencer, Ph.D.\n\nRecipient Title\n\nPresident\u002FOwner\n\nUtah Cord Bank LLC\n\n8675 S Sandy Parkway, Bldg. 110\n\nSandy, UT 84070\n\nUnited States\n\nIssuing Office:\n\nOffice Biological Products Operations – Division 2\n\nUnited States\n\nMay 11, 2021\n\n[Warning Letter #OBPO 21-614021]\n\nDear Dr. Spencer:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Utah Cord Bank, LLC, located at 8675 S Sandy Parkway, Bldg. 110, Sandy, UT 84070 from February 1-11, 2021. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs)1 set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 [21 CFR 1271], and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C 264].\n\nThe deviations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the items discussed below. All items below pertain to HCT\u002FPs recovered from donors between May 25, 2005 and February 11, 2021. Following our review of the information collected during the inspection, we identified additional concerns that are also included below.\n\n1. Failure to validate and approve a process according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests. The validation activities and results must be documented, including the date and signature of the individual(s) approving the validation [21 CFR 1271.230(a)]. For example:\n\na. You failed to validate your process, which cannot be fully verified, used in the manufacture of HCT\u002FPs to ensure that your process does not cause contamination or cross-contamination and prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP.\n\nb. Processing is defined at 21 CFR 1271.3(ff) and includes testing for microorganisms. You failed to validate your microbiological testing, which cannot be fully verified, used in the manufacture of HCT\u002FPs to ensure that your process prevents the introduction, transmission or spread of communicable disease through the use of the HCT\u002FP.\n\n2. Failure to adequately monitor environmental conditions and provide proper conditions for operations, where environmental conditions could reasonably be expected to cause contamination or cross-contamination of HCT\u002FPs or equipment, or accidental exposure of HCT\u002FPs to communicable disease agents [21 CFR 1271.195(c)]. For example, the steps in processing HCT\u002FPs you described to the investigators during the inspection include exposing the unit of cord blood to the environment by draining the umbilical cord blood from the original collection bag into (b)(4) vials. These conditions could reasonably be expected to cause contamination or cross-contamination of the HCT\u002FPs, however, you do not monitor environmental conditions in the (b)(4) for the presence of microorganisms.\n\n3. Failure to establish and maintain procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT\u002FPs. You must design these procedures to prevent circumstances that increase the risk of the introduction, transmission, or spread of communicable diseases through the use of HCT\u002FPs [21 CFR 1271.180(a)]. For example, you have not established and maintained procedures that include, but are not limited to the following:\n\na. Facilities (i.e.: maintenance\u002Frepairs, cleaning, sanitation) [21 CFR 1271.190(d)];\n\nb. Environmental control [21 CFR 1271.195];\n\nc. Equipment (i.e.: maintenance, cleaning, calibration) [21 CFR 1271.200(b)];\n\nd. Verification of supplies and reagents [21 CFR 1271.210];\n\ne. Processing and processing controls [21 CFR 1271.220];\n\nf. Labeling controls [21 CFR 1271.250];\n\ng. Storage [21 CFR 1271.260]; and\n\nh. Receipt, predistribution shipment, and distribution, including release criteria and shipping conditions [21 CFR 1271.265].\n\n4. Failure to maintain records concurrently with the performance of each step required in Subpart D and Subpart C of 21 CFR 1271. The records must identify the person performing the work and the dates of the various entries, and must be as detailed as necessary to provide a complete history of the work performed and to relate the records to the particular HCT\u002FP involved [21 CFR 1271.270(a)]. For example, you have not maintained complete records that include, but are not limited to, the following:\n\na. Facility cleaning and sanitation [21 CFR 1271.190(d)];\n\nb. Environmental control and monitoring activities [21 CFR 1271.195(d)];\n\nc. Equipment maintenance, cleaning, sanitizing, and calibration [21 CFR 1271.200(e)];\n\nd. Receipt, verification, and lot number of each supply and\u002For reagent used in the manufacture of HCT\u002FPs [21 CFR 1271.210(d)];\n\ne. Storage temperatures [21 CFR 1271.260(e)];\n\nf. Recovery [21 CFR 1271.215];\n\ng. Processing (including sterility testing) [21 CFR 1271.220]; and\n\nh. Complaints [21 CFR 1271.320(b)].\n\nBased on the information obtained during the inspection and stated in your FDA 483 correspondence, it is unclear whether your products are intended for autologous use only, or whether they are also intended for allogeneic use in a first-degree or second-degree blood relative. Please clarify all potential uses of your products. Donor-eligibility determination, Subpart – C of 21 CFR 1271, is based on donor screening and testing for relevant communicable disease agents and diseases (described in §1271.50) and is required for all donors used in HCT\u002FPs except as outlined under §1271.90.\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment is in compliance with all the applicable requirements of the federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you fully comply with the law.\n\nWe acknowledge receipt of your letters dated March 5, 2021 and April 16, 2021, in response to the Form FDA 483 issued to you on February 11, 2021. We have reviewed your responses in which you state that you have retained the services of a consultant. However, other than retaining the services of a consultant, your response is silent regarding specific corrective actions to address the violations outlined above.\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your product is not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and time frame within which the remaining corrections will be completed.\n\nYour response should be sent to the following address: Marc Jackson, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, DFC – BLDG 20 – W 6th Ave & Kipling St., Denver, CO 80225, or emailed to Marc.Jackson@fda.hhs.gov. If you should have any questions, please contact Marc Jackson, Compliance Officer at (303) 236-3083 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice Biological Products Operations – Division 2\n\n__________________\n\n1 This letter applies solely to products manufactured for autologous use or, depending on your response to FDA's request at the close of this letter, any products manufactured for allogeneic use in a first-degree or second-degree blood relative. Accordingly, references in this letter to HCT\u002FPs or \"products\" do not include products manufactured by your firm that are not for autologous use or allogeneic use in a first-degree or second-degree blood relative. FDA intends to communicate with Utah Cord Bank, LLC separately regarding these products.","Utah Cord Bank LLC","utah-cord-bank-llc-614021-05112021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-614021-05112021","2026-10-26T08:10:18.701861+00:00","2021-06-01","614021","Biologics","Eliott D. Spencer, Ph.D.","2026-08-20T03:05:47.645+00:00","VIA UNITED PARCEL SERVICE","2021-05-11",{"id":55,"raw":56,"subject":12,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":68,"delivery_method":69,"recipient_title":19,"reference_number":70,"action_taken_date":66,"medical_device_id":19,"response_letter_date":19},672,[57,57,58,11,12,13,13,13],"\u003Ctime datetime=\"2025-09-11T04:00:00Z\">09\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcordova-tobacco-vape-711225-09112025\">Cordova Tobacco &amp; Vape\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501248\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cordova Tobacco &amp; Vape\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1204 North Houston Levee Road Suite 113\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cordova\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38018\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 11, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Cordova Tobacco &amp; Vape sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Fasta Burrst 35000 Frozen Strawberry Banana 5% nicotine.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501248, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501248\n\nProduct:\n\nTobacco\n\nRecipient:\n\nCordova Tobacco & Vape\n\n1204 North Houston Levee Road Suite 113\n\nCordova, TN 38018\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 11, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Cordova Tobacco & Vape sells and\u002For distributes electronic nicotine delivery system (ENDS) products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States the following ENDS products that lack a marketing authorization order: Fasta Burrst 35000 Frozen Strawberry Banana 5% nicotine.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501248, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Cordova Tobacco & Vape","cordova-tobacco-vape-711225-09112025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcordova-tobacco-vape-711225-09112025","2026-10-26T08:08:18.166886+00:00","2025-09-11","711225","2026-08-19T16:25:53.107+00:00","VIA UPS and Electronic Mail","ER2501248",{"id":72,"raw":73,"subject":39,"body_html":79,"body_text":80,"firm_name":81,"letter_id":82,"created_at":44,"fei_number":19,"letter_url":83,"updated_at":84,"action_type":22,"case_status":23,"posted_date":85,"marcs_cms_no":86,"product_type":49,"closeout_date":19,"issuing_office":77,"recipient_name":87,"body_fetched_at":88,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":89,"medical_device_id":19,"response_letter_date":19},3205,[74,75,76,77,78,13,13,13],"\u003Ctime datetime=\"2021-08-17T13:20:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-10T04:00:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-dba-utah-cell-bank-614013-08102021\">Utah Cord Bank LLC dba Utah Cell Bank\u003C\u002Fa>","Office of Biological Products Operations - Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eliott D. Spencer, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Utah Cord Bank LLC dba Utah Cell Bank\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8675 S. Sandy Parkway, Suite 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sandy\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84070-6418\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations - Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 10, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #OBPO 21-614013\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Spencer:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firms, Utah Cord Bank LLC (Utah Cord Bank), dba Utah Cell Bank, and FIOR Bioscience LLC (FIOR Bioscience), co-located at 8675 S. Sandy Parkway, Suite 110, Sandy, UT 84070, conducted between February 1 and February 11, 2021, United States Food and Drug Administration (FDA) investigators documented that you manufacture cellular products for allogeneic use, including: human umbilical cord blood, umbilical cord, and amniotic membrane derived cellular products with the brand names StemVive® and StemMaxx™ (also known as Stemii and Stemshot); a human umbilical cord blood derived product with the brand name StemTru™; and a human umbilical cord derived product with the brand name StemCellect™ (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FIOR Bioscience distributes your products directly to health care professionals and medical facilities. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and at the time of the inspection, including information on the FIOR Bioscience website, https:\u002F\u002Ffiorbio.com reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264].\u003C\u002Fp>\n\n\u003Cp>HCT\u002FPs that do not meet all the criteria set forth in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Your establishments do not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all the criteria in 21 CFR 1271.10(a). Therefore, your products are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, an HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” StemVive® and StemMaxx™ are not intended to perform the same basic function or functions of umbilical cord blood, umbilical cord, or amniotic membrane in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system (for cord blood); serving as a conduit (for umbilical cord); or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using these products to treat orthopedic conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your products fail to meet other criteria set forth in 21 CFR 1271.10(a). For example, StemVive®, StemMaxx™, and StemTru™ fail to meet 21 CFR 1271.10(a)(4). These cellular products, manufactured at least in part from donated umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use. In addition, StemVive®, StemMaxx™, and StemCellect™ fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord and\u002For amniotic membrane related to their utility for reconstruction, repair, or replacement.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210, 211, and 1271.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA 483 to you listing inspectional observations, which described a number of significant deviations from CGMP and CGTP applicable to your products. The deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the aseptic processes used to manufacture over \u003Cstrong>(b)(4) \u003C\u002Fstrong>vials of your StemVive®, StemMaxx™; StemTru™ and StemCellect™ products (i.e., by performing media fill simulations) since your manufacturing operations began. By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. Your employees use non-sterile personal protective equipment (PPE), for example lab coats, gloves and hair nets, during the manufacture of your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to have separate or defined areas or such other control systems for your operations as are necessary to prevent contamination or mixups during the course of aseptic processing. [21 CFR 211.42(c)(10)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You allow two or more operators to process product within the same \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Processing by more than one technician in the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> can significantly increase the potential for contamination.\u003C\u002Fp>\n\n\u003Cp>b. Your manufacturing facility is not classified with respect to air quality. The \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used to process your products, and operator gowning areas are located within an unclassified environment.\u003C\u002Fp>\n\n\u003Cp>c. Your firm has not established an adequate system for monitoring environmental conditions in the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>d. Your firm does not conduct personnel monitoring of operators working in the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>e. Your firm does not have a validated cleaning process for the aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not established scientifically sound and appropriate specifications, standards, sampling plans and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. You do not collect and test sterility samples that are representative of the lot size. You test \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterility and rely on the results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility test to determine lot release despite the lot size, which may consist of as many as \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to include in laboratory records complete data derived from all tests necessary to assure compliance with established specifications and standards, including a statement of each method used in the testing of the sample that indicates the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested [21 CFR 211.194(a)(2)].\u003C\u002Fstrong> Specifically, lot release of your products is based on sterility testing; however, your in-house sterility test has not been validated. Accordingly, your laboratory records do not include a statement that indicates the location of data that establish that your sterility testing methods meet proper standards of accuracy and reliability as applied to your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, the manufacturing processes for your products have not been validated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. There are no written procedures describing in sufficient detail the criteria for approval or rejection of incoming human umbilical cord blood or human umbilical cord.\u003C\u002Fp>\n\n\u003Cp>b. There are no written procedures describing in sufficient detail the acceptance criteria for components used in manufacturing, including \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>micron and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>micron filters, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (glass) bottles, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and drug product containers and closures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm failed to validate the cleaning process for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>b. There are no data or rationale for the cleaning agents used or their rotation for the cleaning of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> where manufacturing is performed.\u003C\u002Fp>\n\n\u003Cp>c. Your firm has not established written procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filter and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> funnel that come into direct contact with your products during processing.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fstrong> Specifically, from July 2017 to January 2020, you failed to thoroughly investigate 16 sterility failures. The failed lots were discarded; however, there was no further evaluation to identify the contaminating microorganism, determine a root cause or determine if other product lots may have been affected by the failures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assign a two-to-six year expiration date to your products without supporting data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Although your firm received multiple complaints regarding your products, there was no supporting documentation to show that you performed an adequate follow-up and\u002For investigation of those complaints. We note that these complaints were categorized as adverse events on your complaint log.\u003C\u002Fp>\n\n\u003Cp>b. Written procedures describing the handling of all written and oral complaints do not include procedures for review of a complaint to determine whether the complaint represents a serious and\u002For unexpected adverse experience.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>11. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your batch production record does not include documentation of the accomplishment of each significant step in the processing of your products as described in your work instructions. These work instructions include GLP-DOC-0008 entitled “Amniotic Membrane Injectable Product Isolation Processing Work Instruction”; GLP-DOC-0009, Revision 01 entitled “Cord Tissue and Blood Injectable Product Isolation Processing Work Instruction”; and GLP-DOC-010 entitled “Cord Tissue Flowable Product Isolation Processing Work Instruction.”\u003C\u002Fp>\n\n\u003Cp>b. The batch production record does not include documentation of the identity of each batch of component or in-process material used in the processing of your products.\u003C\u002Fp>\n\n\u003Cp>c. The batch production record does not consistently document the results of product sterility testing.\u003C\u002Fp>\n\n\u003Cp>d. The batch production record does not include a statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (i.e., the quantity of vials produced in each product lot).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>12. Failure to establish, when appropriate, time limits for the completion of each phase of production to assure the quality of the drug product [21 CFR 211.111].\u003C\u002Fstrong> Specifically, your firm stores \u003Cstrong>(b)(4)\u003C\u002Fstrong> product (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml glass container in a commercial refrigerator in your unclassified lab area for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to aliquoting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> into a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml or \u003Cstrong>(b)(4)\u003C\u002Fstrong> ml final container. Your firm failed to validate the time limit the \u003Cstrong>(b)(4)\u003C\u002Fstrong> can be stored in such a manner without negatively impacting the final product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>13. Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment, including computers, or related systems that will perform a function satisfactorily, that are used in the manufacture, processing, packing and holding of a drug product, according to a written program designed to assure proper performance [21 CFR 211.68(a)].\u003C\u002Fstrong> Specifically, you failed to validate the software used to maintain your sterility testing results according to a written program designed to assure the software’s proper performance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>14. Failure to assign and label each HCT\u002FP that you manufacture with a distinct identification code in accordance with the requirements in 21 CFR 1271.290(c).\u003C\u002Fstrong> Specifically, you do not ensure that each HCT\u002FP that you manufacture is assigned and labeled with a distinct identification code that relates the HCT\u002FP to the donor and to all records pertaining to the HCT\u002FP and that labeling includes information designed to facilitate effective tracking, using the distinct identification code, from the donor to the recipient and from the recipient to the donor.\u003C\u002Fp>\n\n\u003Cp>FDA received your written responses, dated March 5 and April 16, 2021, to the inspectional observations on the Form FDA 483 issued at the conclusion of the inspection, and we have reviewed the contents. FDA acknowledges your commitment to voluntarily cease the manufacture and processing of new HCT\u002FPs until your third-party consultant has reviewed and audited your firm’s processes and procedures. We also acknowledge your commitment to not distribute HCT\u002FPs that remain in inventory until they have been resampled and retested for contamination. These commitments, along with the corrective actions described in the rest of your response, are not adequate to address the above-noted violations.\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nKarlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations - Division 2\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This letter does not pertain to HCT\u002FPs intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. Accordingly, references in this letter to “HCT\u002FPs” or “your products” do not include products you manufacture that are intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. FDA issued a separate Warning Letter to you, dated May 11, 2021, that pertains to those HCT\u002FPs.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nEliott D. Spencer, PhD\n\nRecipient Title\n\nOwner\u002FPresident\n\nUtah Cord Bank LLC dba Utah Cell Bank\n\n8675 S. Sandy Parkway, Suite 110\n\nSandy, UT 84070-6418\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations - Division 2\n\nUnited States\n\nWARNING LETTER\n\nAugust 10, 2021\n\nWarning Letter #OBPO 21-614013\n\nDear Dr. Spencer:\n\nDuring an inspection of your firms, Utah Cord Bank LLC (Utah Cord Bank), dba Utah Cell Bank, and FIOR Bioscience LLC (FIOR Bioscience), co-located at 8675 S. Sandy Parkway, Suite 110, Sandy, UT 84070, conducted between February 1 and February 11, 2021, United States Food and Drug Administration (FDA) investigators documented that you manufacture cellular products for allogeneic use, including: human umbilical cord blood, umbilical cord, and amniotic membrane derived cellular products with the brand names StemVive® and StemMaxx™ (also known as Stemii and Stemshot); a human umbilical cord blood derived product with the brand name StemTru™; and a human umbilical cord derived product with the brand name StemCellect™ (collectively, “your products”).1 FIOR Bioscience distributes your products directly to health care professionals and medical facilities. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and at the time of the inspection, including information on the FIOR Bioscience website, https:\u002F\u002Ffiorbio.com reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264].\n\nHCT\u002FPs that do not meet all the criteria set forth in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nYour establishments do not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all the criteria in 21 CFR 1271.10(a). Therefore, your products are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, an HCT\u002FP meets the criterion in 21 CFR 1271.10(a)(2) if the HCT\u002FP is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” StemVive® and StemMaxx™ are not intended to perform the same basic function or functions of umbilical cord blood, umbilical cord, or amniotic membrane in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system (for cord blood); serving as a conduit (for umbilical cord); or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using these products to treat orthopedic conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your products fail to meet other criteria set forth in 21 CFR 1271.10(a). For example, StemVive®, StemMaxx™, and StemTru™ fail to meet 21 CFR 1271.10(a)(4). These cellular products, manufactured at least in part from donated umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use. In addition, StemVive®, StemMaxx™, and StemCellect™ fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord and\u002For amniotic membrane related to their utility for reconstruction, repair, or replacement.\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA), nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210, 211, and 1271.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA 483 to you listing inspectional observations, which described a number of significant deviations from CGMP and CGTP applicable to your products. The deficiencies include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. Your firm failed to validate the aseptic processes used to manufacture over (b)(4) vials of your StemVive®, StemMaxx™; StemTru™ and StemCellect™ products (i.e., by performing media fill simulations) since your manufacturing operations began. By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\n\nb. Your employees use non-sterile personal protective equipment (PPE), for example lab coats, gloves and hair nets, during the manufacture of your products.\n\n2. Failure to have separate or defined areas or such other control systems for your operations as are necessary to prevent contamination or mixups during the course of aseptic processing. [21 CFR 211.42(c)(10)]. For example:\n\na. You allow two or more operators to process product within the same (b)(4). Processing by more than one technician in the same (b)(4) can significantly increase the potential for contamination.\n\nb. Your manufacturing facility is not classified with respect to air quality. The (b)(4), used to process your products, and operator gowning areas are located within an unclassified environment.\n\nc. Your firm has not established an adequate system for monitoring environmental conditions in the aseptic processing area where your products are manufactured.\n\nd. Your firm does not conduct personnel monitoring of operators working in the aseptic processing area where your products are manufactured.\n\ne. Your firm does not have a validated cleaning process for the aseptic processing area where your products are manufactured.\n\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example:\n\na. You have not established scientifically sound and appropriate specifications, standards, sampling plans and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\n\nb. You do not collect and test sterility samples that are representative of the lot size. You test (b)(4) for sterility and rely on the results of (b)(4) sterility test to determine lot release despite the lot size, which may consist of as many as (b)(4) vials.\n\n4. Failure to include in laboratory records complete data derived from all tests necessary to assure compliance with established specifications and standards, including a statement of each method used in the testing of the sample that indicates the location of data that establish that the methods used in the testing of the sample meet proper standards of accuracy and reliability as applied to the product tested [21 CFR 211.194(a)(2)]. Specifically, lot release of your products is based on sterility testing; however, your in-house sterility test has not been validated. Accordingly, your laboratory records do not include a statement that indicates the location of data that establish that your sterility testing methods meet proper standards of accuracy and reliability as applied to your products.\n\n5. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, the manufacturing processes for your products have not been validated.\n\n6. Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)]. For example:\n\na. There are no written procedures describing in sufficient detail the criteria for approval or rejection of incoming human umbilical cord blood or human umbilical cord.\n\nb. There are no written procedures describing in sufficient detail the acceptance criteria for components used in manufacturing, including (b)(4) micron and (b)(4) micron filters, (b)(4) (glass) bottles, and (b)(4), and drug product containers and closures.\n\n7. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)]. For example:\n\na. Your firm failed to validate the cleaning process for your (b)(4).\n\nb. There are no data or rationale for the cleaning agents used or their rotation for the cleaning of the (b)(4) where manufacturing is performed.\n\nc. Your firm has not established written procedures for the (b)(4) sterilization of the (b)(4) filter and the (b)(4) funnel that come into direct contact with your products during processing.\n\n8. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically, from July 2017 to January 2020, you failed to thoroughly investigate 16 sterility failures. The failed lots were discarded; however, there was no further evaluation to identify the contaminating microorganism, determine a root cause or determine if other product lots may have been affected by the failures.\n\n9. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assign a two-to-six year expiration date to your products without supporting data.\n\n10. Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]. For example:\n\na. Although your firm received multiple complaints regarding your products, there was no supporting documentation to show that you performed an adequate follow-up and\u002For investigation of those complaints. We note that these complaints were categorized as adverse events on your complaint log.\n\nb. Written procedures describing the handling of all written and oral complaints do not include procedures for review of a complaint to determine whether the complaint represents a serious and\u002For unexpected adverse experience.\n\n11. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)]. For example:\n\na. Your batch production record does not include documentation of the accomplishment of each significant step in the processing of your products as described in your work instructions. These work instructions include GLP-DOC-0008 entitled “Amniotic Membrane Injectable Product Isolation Processing Work Instruction”; GLP-DOC-0009, Revision 01 entitled “Cord Tissue and Blood Injectable Product Isolation Processing Work Instruction”; and GLP-DOC-010 entitled “Cord Tissue Flowable Product Isolation Processing Work Instruction.”\n\nb. The batch production record does not include documentation of the identity of each batch of component or in-process material used in the processing of your products.\n\nc. The batch production record does not consistently document the results of product sterility testing.\n\nd. The batch production record does not include a statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (i.e., the quantity of vials produced in each product lot).\n\n12. Failure to establish, when appropriate, time limits for the completion of each phase of production to assure the quality of the drug product [21 CFR 211.111]. Specifically, your firm stores (b)(4) product ((b)(4)) in a (b)(4) ml glass container in a commercial refrigerator in your unclassified lab area for up to (b)(4) prior to aliquoting the (b)(4) into a (b)(4) ml or (b)(4) ml final container. Your firm failed to validate the time limit the (b)(4) can be stored in such a manner without negatively impacting the final product.\n\n13. Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment, including computers, or related systems that will perform a function satisfactorily, that are used in the manufacture, processing, packing and holding of a drug product, according to a written program designed to assure proper performance [21 CFR 211.68(a)]. Specifically, you failed to validate the software used to maintain your sterility testing results according to a written program designed to assure the software’s proper performance.\n\n14. Failure to assign and label each HCT\u002FP that you manufacture with a distinct identification code in accordance with the requirements in 21 CFR 1271.290(c). Specifically, you do not ensure that each HCT\u002FP that you manufacture is assigned and labeled with a distinct identification code that relates the HCT\u002FP to the donor and to all records pertaining to the HCT\u002FP and that labeling includes information designed to facilitate effective tracking, using the distinct identification code, from the donor to the recipient and from the recipient to the donor.\n\nFDA received your written responses, dated March 5 and April 16, 2021, to the inspectional observations on the Form FDA 483 issued at the conclusion of the inspection, and we have reviewed the contents. FDA acknowledges your commitment to voluntarily cease the manufacture and processing of new HCT\u002FPs until your third-party consultant has reviewed and audited your firm’s processes and procedures. We also acknowledge your commitment to not distribute HCT\u002FPs that remain in inventory until they have been resampled and retested for contamination. These commitments, along with the corrective actions described in the rest of your response, are not adequate to address the above-noted violations.\n\nYour response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the Form FDA 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facilities. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations - Division 2\n\n______________________________\n\n1 This letter does not pertain to HCT\u002FPs intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. Accordingly, references in this letter to “HCT\u002FPs” or “your products” do not include products you manufacture that are intended for autologous use or allogeneic use in a first-degree or second-degree blood relative. FDA issued a separate Warning Letter to you, dated May 11, 2021, that pertains to those HCT\u002FPs.","Utah Cord Bank LLC dba Utah Cell Bank","utah-cord-bank-llc-dba-utah-cell-bank-614013-08102021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Futah-cord-bank-llc-dba-utah-cell-bank-614013-08102021","2026-10-26T08:10:18.765289+00:00","2021-08-17","614013","Eliott D. Spencer, PhD","2026-08-20T02:41:41.014+00:00","2021-08-10",4,{"510k":92,"classification":93,"enforcement":94,"event":95,"event_backfill":96,"pma":97,"warning_letter":98},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]